Shares of Cronos Group Inc. (NASDAQ:CRON – Get Free Report) have been assigned an average rating of “Hold” from the five brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $2.30.
Several research analysts recently commented on CRON shares. Wall Street Zen upgraded shares of Cronos Group from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. TD Securities reiterated a “buy” rating on shares of Cronos Group in a report on Tuesday, May 12th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Cronos Group in a report on Friday, May 29th.
Institutional Inflows and Outflows
Cronos Group Stock Performance
Cronos Group stock opened at $2.81 on Monday. The company has a market capitalization of $1.05 billion, a P/E ratio of 281.28 and a beta of 0.89. The firm’s fifty day simple moving average is $2.70 and its 200-day simple moving average is $2.66. Cronos Group has a 1-year low of $1.89 and a 1-year high of $3.43.
Cronos Group (NASDAQ:CRON – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01. The business had revenue of $58.97 million for the quarter, compared to the consensus estimate of $42.20 million. Cronos Group had a negative net margin of 1.14% and a negative return on equity of 1.26%. On average, equities research analysts predict that Cronos Group will post 0.07 earnings per share for the current year.
About Cronos Group
Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.
The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.
Featured Articles
- Five stocks we like better than Cronos Group
- As Stablecoins Keep Growing, These 2 Stocks Benefit
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.
